Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$671M |
| 2 |
McDonald's
MCD
|
+$636M |
| 3 |
TSMC
TSM
|
+$515M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$465M |
| 5 |
Colgate-Palmolive
CL
|
+$458M |
Top Sells
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.45% |
| 2 | Healthcare | 11.94% |
| 3 | Consumer Discretionary | 11.58% |
| 4 | Consumer Staples | 10.68% |
| 5 | Financials | 9.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
McDonald's
MCD
$188B
| $629M | 1.65% |
+6,354,900
| New | +$636M |
|
|
2
Eli Lilly
LLY
$1.04T
| $605M | 1.59% |
+12,326,205
| New | +$671M |
|
|
3
TSMC
TSM
$2.19T
| $512M | 1.34% |
+27,950,671
| New | +$515M |
|
|
4
Colgate-Palmolive
CL
$73.7B
| $442M | 1.16% |
+7,707,800
| New | +$458M |
|
|
NVO
5
Novo Nordisk
NVO
$216B
| $433M | 1.14% |
+27,946,000
| New | +$465M |
|
6
Bristol-Myers Squibb
BMY
$125B
| $381M | 1% |
+8,530,800
| New | +$370M |
|
|
LLTC
7
DELISTED
Linear Technology Corp
LLTC
| $367M | 0.96% |
+9,972,600
| New | +$366M |
|
8
Hershey
HSY
$34.9B
| $345M | 0.9% |
+3,859,700
| New | +$341M |
|
9
Intel
INTC
$531B
| $332M | 0.87% |
+13,701,200
| New | +$324M |
|
10
Biogen
BIIB
$29.8B
| $300M | 0.79% |
+1,393,500
| New | +$298M |
|
11
Apple
AAPL
$4.77T
| $283M | 0.74% |
+20,005,636
| New | +$308M |
|
|
WFM
12
DELISTED
Whole Foods Market Inc
WFM
| $270M | 0.71% |
+5,239,948
| New | +$253M |
|
13
Philip Morris
PM
$301B
| $267M | 0.7% |
+3,080,700
| New | +$286M |
|
|
CELG
14
DELISTED
Celgene Corp
CELG
| $262M | 0.69% |
+4,478,538
| New | +$270M |
|
15
Alaska Air
ALK
$4.8B
| $239M | 0.63% |
+9,180,200
| New | +$271M |
|
16
Walmart Inc
WMT
$868B
| $236M | 0.62% |
+9,518,400
| New | +$244M |
|
17
TJX Companies
TJX
$172B
| $232M | 0.61% |
+9,277,600
| New | +$229M |
|
18
Mastercard
MA
$474B
| $222M | 0.58% |
+3,872,000
| New | +$215M |
|
19
IBM
IBM
$197B
| $211M | 0.55% |
+1,154,889
| New | +$225M |
|
20
Microsoft
MSFT
$2.89T
| $199M | 0.52% |
+5,760,284
| New | +$189M |
|
|
DTV
21
DELISTED
DIRECTV COM STK (DE)
DTV
| $198M | 0.52% |
+3,218,992
| New | +$193M |
|
22
CF Industries
CF
$19.4B
| $190M | 0.5% |
+5,552,750
| New | +$207M |
|
23
Verizon
VZ
$186B
| $188M | 0.49% |
+3,744,017
| New | +$191M |
|
|
DO
24
DELISTED
Diamond Offshore Drilling
DO
| $188M | 0.49% |
+2,734,000
| New | +$188M |
|
25
VeriSign
VRSN
$23.7B
| $184M | 0.48% |
+4,109,876
| New | +$190M |
|
Similar funds
Renaissance Technologies's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for Renaissance Technologies, which disclosed 2,756 positions worth $38.1B. Its ten largest holdings account for 11% of the portfolio.
Its largest position is Eli Lilly: 12,326,205 shares worth $605M.
By sector, the portfolio is most concentrated in Technology at 14% of assets, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2013 buy was Eli Lilly: 12,326,205 shares worth $605M.
- Renaissance Technologies's ten largest holdings make up 11% of its $38.1B portfolio in Q2 2013.
- Renaissance Technologies disclosed 2,756 positions in Q2 2013, its first 13F filing on record.
Based on Renaissance Technologies's 13F filing for Q2 2013, filed 12 Aug 2013.